IC-270

**IC-270** is an investigational ophthalmic fixed-dose combination eye drop being developed for allergic conjunctivitis. It combines **IC-265**, a selective small-molecule **spleen tyrosine kinase inhibitor**, with an **antihistamine agent** to address multiple components of ocular allergy: the Syk-inhibitory component is intended to reduce redness and inflammatory signaling, while the antihistamine component is intended to control itching and other histamine-mediated symptoms. The program originated at **IACTA Pharmaceuticals** and was licensed to **Zhaoke Ophthalmology** for development, manufacture, and commercialization in Greater China and certain Southeast Asian territories. Available company pipeline information indicates Phase 2 development for allergic conjunctivitis.